open access

Vol 14, No 1 (2017)
Review paper
Published online: 2017-03-01
Get Citation

Sexual dysfunction in patients with schizophrenia

Jacek Chojnowski, Magdalena Więdłocha, Anna Mosiołek
Psychiatria 2017;14(1):35-39.

open access

Vol 14, No 1 (2017)
Prace poglądowe - nadesłane
Published online: 2017-03-01

Abstract

We already know a lot about the disease processes at the neurochemical level in schizophrenia. The course of schizophrenia is dependent on such factors as applied medication, psychotherapy, availability of care, the environment in which the patient lives and others. Sexuality of the patients suffering from schizophrenia, as research indicates, is an important phenomenon. Unfortunately, it still takes too little attention from physicians. Patients may sometimes feel uncomfortable addressing such topics with their physicians. It can be caused by fear of other people, sometimes it is due to the sense of shame or lack of trust and in some situations patients think that talking about the illness is more important than anything else. This article shows the influence of the most important factors, associated with schizophrenia, on the sexual functioning of patients. In addition, it shows how great influence on the disease process has sexuality and how it can be modified by the inclusion of drugs.

Abstract

We already know a lot about the disease processes at the neurochemical level in schizophrenia. The course of schizophrenia is dependent on such factors as applied medication, psychotherapy, availability of care, the environment in which the patient lives and others. Sexuality of the patients suffering from schizophrenia, as research indicates, is an important phenomenon. Unfortunately, it still takes too little attention from physicians. Patients may sometimes feel uncomfortable addressing such topics with their physicians. It can be caused by fear of other people, sometimes it is due to the sense of shame or lack of trust and in some situations patients think that talking about the illness is more important than anything else. This article shows the influence of the most important factors, associated with schizophrenia, on the sexual functioning of patients. In addition, it shows how great influence on the disease process has sexuality and how it can be modified by the inclusion of drugs.

Get Citation

Keywords

schizophrenia, sexuality, treatment

About this article
Title

Sexual dysfunction in patients with schizophrenia

Journal

Psychiatria (Psychiatry)

Issue

Vol 14, No 1 (2017)

Article type

Review paper

Pages

35-39

Published online

2017-03-01

Bibliographic record

Psychiatria 2017;14(1):35-39.

Keywords

schizophrenia
sexuality
treatment

Authors

Jacek Chojnowski
Magdalena Więdłocha
Anna Mosiołek

References (23)
  1. de Boer MK, Castelein S, Wiersma D, et al. The facts about sexual (Dys)function in schizophrenia: an overview of clinically relevant findings. Schizophr Bull. 2015; 41(3): 674–686.
  2. Malik P, Kemmler G, Hummer M, et al. EUFEST Study Group. Sexual dysfunction in first-episode schizophrenia patients: results from European First Episode Schizophrenia Trial. J Clin Psychopharmacol. 2011; 31(3): 274–280.
  3. Strauss B, Gross J. [Psychotropic drug-induced changes in sexuality--frequency and relevance in psychiatric practice]. Psychiatr Prax. 1984; 11(2): 49–55.
  4. McCann E. The expression of sexuality in people with psychosis: breaking the taboos. J Adv Nurs. 2000; 32(1): 132–138.
  5. Knegtering H, van den Bosch R, Castelein S, et al. Are sexual side effects of prolactin-raising antipsychotics reducible to serum prolactin? Psychoneuroendocrinology. 2008; 33(6): 711–717.
  6. Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol. 2011; 26(3): 130–140.
  7. Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol. 2008; 23(3): 201–209.
  8. Fan X, Henderson DC, Chiang E, et al. Sexual functioning, psychopathology and quality of life in patients with schizophrenia. Schizophr Res. 2007; 94(1-3): 119–127.
  9. Dossenbach M, Dyachkova Y, Pirildar S, et al. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur Psychiatry. 2006; 21(4): 251–258.
  10. Compton MT, Miller AH. Priapism associated with conventional and atypical antipsychotic medications: a review. J Clin Psychiatry. 2001; 62(5): 362–366.
  11. Arias-Carrión O, Poppel E. Dopamine, learning and reward¬seeking behavior. Act Neurobiol Exp 2007, 67(4): 481–488.
  12. Canuso CM, Goldstein JM, Wojcik J, et al. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res. 2002; 111(1): 11–20.
  13. Bancroft J. Endocrinology of sexual function. Clin Obstet Gynaecol. 1980; 7(2): 253–281.
  14. Konarzewska B, Wołczyński S, Szulc A, et al. Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia. Psychoneuroendocrinology. 2009; 34(1): 129–139.
  15. Smith SM, O'Keane V, Murray R. Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry. 2002; 181: 49–55.
  16. Kapur S, Langlois X, Vinken P, et al. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther. 2002; 302(3): 1129–1134.
  17. Westheide J, Cohen S, Bender S, et al. Sexual dysfunction in psychiatric inpatients the role of antipsychotic medication. Pharmacopsychiatry. 2007; 40(4): 140–145.
  18. Westheide J, Cvetanovska G, Albrecht C, et al. Prolactin, subjective well-being and sexual dysfunction: an open label observational study comparing quetiapine with risperidone. J Sex Med. 2008; 5(12): 2816–2826.
  19. Kennedy SH, Rizvi S. Sexual dysfunction, depression, and the impact of antidepressants. J Clin Psychopharmacol. 2009; 29(2): 157–164.
  20. Nunes LV, Moreira HC, Razzouk D, et al. Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. J Sex Marital Ther. 2012; 38(3): 281–301.
  21. Hanssens L, L'Italien G, Loze JY, et al. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC Psychiatry. 2008; 8: 95.
  22. Nakonezny PA, Byerly MJ, Rush AJ. The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind trial of risperidone vs. quetiapine. J Sex Marital Ther. 2007; 33(3): 203–216.
  23. Byerly MJ, Nakonezny PA, Rush AJ. Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial. Psychiatry Res. 2008; 159(1-2): 115–120.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest Via Medica sp. z o.o. sp. komandytowa, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl